U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07128914) titled 'A Clinical Study of GO306 in Patients With Advanced Solid Tumors' on July 14.
Brief Summary: This study employs a single-arm, open-label, non-randomized, dose-escalation design to investigate the safety, tolerability, and efficacy of GO306 Recombinant Oncolytic Vaccinia Virus Injection.
* Part 1: Utilizes the 3+3 design principle to evaluate the safety and tolerability of a single administration of GO306 at different dose levels. The primary goal is to determine the Maximum Tolerated Dose (MTD), providing the basis for selecting the Recommended Phase 2 Dose (RP2D).
* Part 2: Evaluates the safety and tolerability of repeated intrat...